Renaissance Technologies LLC Lowers Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Renaissance Technologies LLC trimmed its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,946,238 shares of the company’s stock after selling 129,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.79% of GoodRx worth $22,981,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GDRX. Beacon Capital Management LLC bought a new stake in shares of GoodRx during the first quarter valued at approximately $28,000. Plato Investment Management Ltd bought a new stake in shares of GoodRx during the 2nd quarter valued at $43,000. Gerber LLC purchased a new stake in shares of GoodRx in the 4th quarter worth about $75,000. Schnieders Capital Management LLC bought a new position in shares of GoodRx in the 1st quarter worth about $93,000. Finally, Innealta Capital LLC purchased a new position in GoodRx during the 4th quarter valued at about $91,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Stock Down 2.4 %

Shares of GoodRx stock opened at $6.91 on Friday. GoodRx Holdings, Inc. has a twelve month low of $4.14 and a twelve month high of $9.26. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The company’s 50 day moving average is $7.97 and its 200 day moving average is $7.59. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -691.00, a price-to-earnings-growth ratio of 3.55 and a beta of 1.38.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business earned $0.02 earnings per share. Research analysts anticipate that GoodRx Holdings, Inc. will post 0.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GDRX shares. UBS Group decreased their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a report on Friday, August 9th. Citigroup reduced their price target on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Finally, Morgan Stanley upped their price target on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and an average price target of $9.36.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.17% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.